| INTRODUCTION
Pulmonary arterial hypertension (PAH) is a progressive pulmonary vascular condition that can lead to right ventricular failure and premature death. 1 The characteristic increase in pulmonary vascular resistance (PVR) results from the combination of smooth muscle and endothelial cell proliferation, vasoconstriction, fibrosis, and in-situ thrombosis. 2 Over the last three decades, 10 therapeutic agents have received Food and Drug Administration (FDA) approval for use in PAH. 3, 4 Supportive therapies such as oxygen, diuretics, and anticoagulants are commonly used in patients with PAH. The rationale to use anticoagulants derives from postmortem studies of patients with idiopathic pulmonary hypertension (IPAH) that demonstrated in-situ thrombosis. [5] [6] [7] In addition, there is evidence of abnormalities of the platelet activation, coagulation, and fibrinolytic pathways in IPAH patients. [8] [9] [10] [11] [12] [13] These findings, coupled with evidence from retrospective studies demonstrating a benefit of anticoagulation, have justified the use of oral anticoagulation in PAH patients.
There are no randomized controlled studies that evaluate the effectiveness and risks of oral anticoagulation in patients with PAH.
14 Furthermore, limited information exists on the impact of oral anticoagulants in patients with PAH receiving disease-specific therapies. This is striking because some coagulation abnormalities in PAH patients can be improved with PAH-specific therapies. 12, [15] [16] [17] [18] Retrospective studies, mostly performed before the availability of PAH-specific therapies, suggest that oral anticoagulants increase survival in PAH. 6, 19, 20 More contemporary studies corroborated that warfarin use was associated with improved survival, 21 particularly at one year. 22 Two systematic reviews (one with meta-analysis) revealed that anticoagulation decreases mortality risk in PAH patients. 23, 24 The Comparative Prospective Registry of Newly Initiated Therapies for pulmonary hypertension (COMPERA) registry reported that the use of oral anticoagulants was associated with a three-year survival benefit only in patients with IPAH. 25 However, results from Johnson et al. 26 and the
Registry to Evaluate Early and Long-term PAH Disease Management
(REVEAL) registry 27 have recently challenged these findings, questioning the effectiveness of anticoagulation in patients with PAH-even in patients with IPAH.
Studies have shown that chronic treatment of PAH with parenteral prostanoids produces a measurable and consistent antiplatelet effect 28, 29 and may normalize the coagulation/fibrinolysis balance observed in PAH patients
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; factors which could weaken the beneficial effects and increase the bleeding risks of anticoagulation. Therefore, it remains unclear whether PAH patients treated with prostacyclin analogues experience any additional benefit from anticoagulation that outweighs the bleeding risks. Given that a randomized study assessing the risk and benefit of warfarin in PAH patients is unlikely to occur, retrospective studies using data from well-structured patient registries and modern statistical methodologies are the best next alternative. In the present study, our aim was 2-fold: (1) whether warfarin reduces mortality and (2) whether warfarin is associated with a higher risk of bleeding in a large cohort of PAH patients treated with subcutaneous treprostinil. 30 
| METHODS

| Patients and study design
We used the long-term data from an open-label extension study of all the PAH groups and for the patients with IPAH. We also performed sensitivity analyses testing survival based on groups matched on newly generated propensity scores, including three subgroups (1) patients in whom the date of PAH diagnosis was available, (2) subjects that receive warfarin throughout the course of the study (without stops), and (3) individuals who were followed during the entire course of the study or died. Adverse events were recorded through the study. All P-values are two-tailed, and a value of <.05 was considered statistically significant.
| Statistical analysis
The statistical analyses were performed using the Statistical Analysis System (SAS) 9.3, SAS Institute Inc., Cary, NC, USA.
| RESULTS
| Patient characteristics
We included 860 patients of whom 425 (49%) had IPAH. The mean age was 46±15 years and 653 (76%) patients were female. Most of the patients were in NYHA functional class II or III (n=782, 91%). Functional and hemodynamic characteristics are shown in Table 1 . A total of 590 (69%) patients received warfarin during the study and 270 (31%) did not. Baseline characteristics of these two groups are presented in Table 1 . The proportions of women, African American race, and IPAH patients were higher in those individuals receiving warfarin. A higher proportion of patients with congenital heart disease and portopulmonary hypertension did not receive warfarin. NYHA functional class and most of hemodynamic determinations were similar between the groups; however, the mPAP was higher in subjects who did not receive warfarin. When only considering patients with IPAH (n=425), we noted no significant demographic differences in the group that received warfarin (n=311, 73%) vs the group that did not (n=114, 27%) (Table S1 ).
| Warfarin treatment
Of the 590 patients in the warfarin group, 370 (63%) were on warfarin for the full duration of the subject's participation. Baseline characteristics of these subjects are presented in Table S2 . A total of 489 patients had no stops (complete cessation of warfarin treatment) recorded in their warfarin administration and received it for a mean±SD (range) of 544±405 (3-1579) days. Of note, it is possible that patients began treatment with warfarin after being enrolled in the study. For example, a patient started warfarin one year after beginning treatment with treprostinil; therefore in this case, the patient did not receive treatment for the full duration of the study but had no stops (once the medication was initiated) during the remainder of the study time. Eighty-five patients had one stop in warfarin administration and received it for 734±495 (38-2219) days. Twelve patients had two recorded stops in warfarin and received it for 988±508 days. Four patients had ≥3 stops. Table S3 demonstrates PAH patients who remained throughout the study and in which treatment was not prematurely discontinued.
| Impact of warfarin treatment
| Survival analysis
The Kaplan-Meier survival analysis for PAH patients receiving warfarin vs those not receiving warfarin is presented in Figure 2 , panel 
| Propensity score matching
Due to missing values, 433 of 590 PAH patients on warfarin had a propensity score. Based on the propensity score, we matched 433
PAH patients who received warfarin with patients drawn from the group who did not receive this treatment, using matching with replacement to balance the groups (ie, a single control may appear several times to match different cases). After propensity score matching, baseline characteristics were balanced except for RA pressure (Table   S4 ). The use of warfarin had no significant impact on survival (log-rank P=.37, Figure 2 , panel A). After imputing missing data, we generated propensity scores for all PAH patients who received warfarin (n=590).
This group was then matched with patients drawn from the PAH group not on warfarin. After imputation and propensity score matching, baseline characteristics were balanced (Table S5) . Similarly, the use of warfarin had no significant impact on survival (log-rank P=.72).
We performed three sensitivity analyses. The first analysis consisted vs 28±48 (median 11) months for the groups on no warfarin and warfarin, respectively (P=.56). Importantly, no significant survival differences were noted between the groups (log-rank test P=.53, Fig. S2 ).
The second analysis involved a propensity score matching comprising patients who received warfarin through the course of the study (n=256 in each group). All variables were well balanced between the groups except of RA pressure (10±6 and 11±6 for the groups on no warfarin and warfarin, respectively). No survival differences were noted between the no warfarin and warfarin groups (log-rank P=.66, Figure 2B ). The last sensitivity analysis matched the propensity score in patients who stayed throughout the entire course of the study or T A B L E 1 Baseline characteristics of entire cohort died (we excluded patients that prematurely dropped out of the study).
For this analysis, we included 233 patients in each group. The two groups were well balanced including RA pressure (P=.16). Similarly, no survival differences were noted between the no warfarin and warfarin groups (log-rank P=.34, Figure 2C ).
| Adverse effects of warfarin treatment
Hemorrhagic events that were not related to the infusion site were not ostensibly related to the dose of treprostinil (Table 2 ). Only two events were severe, leading to hospitalization: gastrointestinal hemorrhage and epistaxis. Thrombocytopenia was attributed to treprostinil treatment in six (0.7%) patients with one related hospitalization and two considered a severe event.
| DISCUSSION
The present study builds upon the growing body of literature that warfarin does not appear to provide a survival advantage in patients with PAH. Using long-term data from an open-label study on PAH patients treated with subcutaneous treprostinil, 30 we found that patients receiving anticoagulation during the study had similar survival to those individuals who were not receiving this treatment. This observation held true even when we adjusted our analyses for different variables of interest or matched groups using propensity scores. In fact, the use of warfarin was not significantly associated with survival in the subgroup of patients with IPAH, individuals that received warfarin during the entire course of the study, or remained in the study without early discontinuation. 
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In our study, 590 (69%) patients with PAH received warfarin. The proportion of subjects receiving warfarin was higher in women and patients with IPAH. Warfarin use was less frequent in individuals with PAH associated with congenital heart disease or portopulmonary hypertension. Anticoagulation in patients with PAH is largely driven by composite information from other large-scale retrospective analyses.
The COMPERA registry 25 included 1283 consecutive adult patients with newly diagnosed PAH between July 2007 and April 2013. A total of 738 (57.5%) patients received anticoagulation but only two percent of the patients received prostacyclin analogues. Three-year survival was better in IPAH patients that received anticoagulation vs those that never received it. Conversely, anticoagulants did not demonstrate a significant survival benefit in patients with other forms of PAH and potentially a trend toward increased mortality. In our analysis, we did not notice a survival difference based on the use of warfarin, both in the overall cohort or in the subjects with IPAH. It should be noted that our results are primarily based on patients with NYHA class II and III as limited patients were available in other groups to draw valid conclusions.
The benefit of anticoagulation in patients with PAH was recently examined in the REVEAL. Preston et al. 27 assessed the effect of warfarin on survival of patients with IPAH and systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH). A total of 187 patients receiving warfarin were matched 1:1 with patients never on warfarin. They found no significant survival advantage in any of these two groups of PAH patients when compared to matched controls, corroborating the results from our study. Furthermore, they found that longterm warfarin use in SSc-PAH patients was associated with poorer survival than patients not receiving warfarin, even after adjusting for confounders.
The available evidence shows that warfarin is not beneficial in patients with SSc-PAH. [25] [26] [27] In patients with IPAH who received parenteral prostacyclin analogues, the use of warfarin is likely not beneficial. This is supported by our results and the fact that one of the reasons for the discordant findings between the COMPERA and REVEAL studies might be the higher use of parenteral prostacyclin analogues in the latter (46% vs 2%, respectively). The lack of effect of warfarin in patients on parenteral prostacyclin analogue therapy could be due to the fact that prostacyclin analogues have antiplatelet effects, 34-36 decrease plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1, 16 and normalize plasma markers of endothelial cell injury.
12
A systemic review of 12 nonrandomized studies evaluating survival in patients with IPAH, anorexigen-induced PAH, and CTD-PAH treated with anticoagulation demonstrated a mortality benefit in IPAH in six of 12 studies. The authors noted that earlier studies tended to show a benefit, but many of these studies were limited by cohort heterogeneity, small sample size, and patient and treatment selection biases. More recent studies concluded that anticoagulation may not be beneficial, particularly in patients with CTD-PAH, as noted in our study.
Results of this study should not be extrapolated to anticoagulants other than warfarin. It is possible that direct coagulation factor inhibitors such as apixaban, rivaroxaban, edoxaban, and dabigatran may alter the risk/benefit ratio when used in PAH patients. Unlike warfarin, these drugs are fixed dose, have a predictable anticoagulant effect that eliminates the need for routine monitoring, and have few drug or dietary interactions. Limited research has been performed in PAH with these novel anticoagulants. Delbeck et al. 37 showed that the chronic use of rivaroxaban reduced systolic RV pressure increase and prevented RV hypertrophy in a monocrotaline pulmonary hypertension rat model.
Anticoagulation is also not without side effects, given reported bleeding rates of 5.4 and 19 per 100 patient-years in IPAH-and CTDassociated PAH, respectively, 38 which is higher than the reported risk in chronic thromboembolic pulmonary hypertension (2.4 per 100 patient-years). 38 The risk of bleeding is increased in patients with systemic sclerosis 39 ; in fact, one study found a 70% probability that warfarin provides no significant benefit or might be harmful in these patients. 26 Ogawa et al. 40 reported frequent hemorrhagic complications in IPAH patients treated with anticoagulation and epoprostenol suggesting that this combination of therapy may increase the bleeding risk. In the present study, we did not observe a higher incidence of major bleeding complication in patients receiving warfarin; however, we did note a higher proportion of soft tissue bleeding at the injection site. 42 The present study suggests that oral warfarin does not appear to provide a survival advantage in PAH patients receiving subcutaneous treprostinil therapy. This finding is important given that many practitioners commonly prescribe warfarin to these patients.
Limitations of the present study include (1) the lack of randomization based on the use of anticoagulation, (2) the time on target INR
was not recorded, (3) reasons for giving or withholding anticoagulation were not available, (4) we only included PAH patients treated with treprostinil, and (5) the criteria used to decide not to anticoagulate patients was not stated and the target INR levels were not recorded.
However, a systematic review and meta-regression of 67 studies totaling 50 208 patients followed for 57 155 patient-years demonstrated that the INR is in the therapeutic range for an average of 64% of the time. 43 We believe that this percentage could be used as a reference point for our study. It remains unclear whether a more strict INR control, leading to longer times in the therapeutic INR range, could have demonstrated a survival benefit; nevertheless, our results reflect the effect of warfarin as used in real-world clinical practice. Despite these limitations, our study is certainly important, as most PH centers continue to use anticoagulation for IPAH patients treated with prostacyclin analogues, 44 an approach that might not be necessary. In the absence of a randomized control trial, observational studies using propensity score matching to balance the study groups are the best contemporary alternative to fill this gap in knowledge.
| CONCLUSION
Long-term use of warfarin was not associated with survival in PAH or idiopathic PAH patients treated with subcutaneous treprostinil.
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